AMPHENOL CORP /DE/ Financials
Quarterly XBRL submissions from SEC 10-K and 10-Q filings.
Income Statement (Last 8 Quarters)
(3)| Period | Revenue | YoY % | Net Income | YoY % | Operating Income | EPS |
|---|---|---|---|---|---|---|
| Q3 FY202510-Q · 2025-09-30 | $6.2B | — | $1.2B | — | $1.7B | $0.97 |
| Q2 FY202510-Q · 2025-06-30 | $24.2M | — | $1.1B | — | $1.5B | $0.86 |
| Q1 FY202510-Q · 2025-03-31 | $2.4B | — | $737.8M | — | $204.5M | $0.58 |
Balance Sheet
| Period | Total Assets | Total Liabilities | Cash & Equivalents | Shareholders Equity |
|---|---|---|---|---|
| Q3 FY202510-Q | $27.1B | $14.5B | $3.8B | $12.5B |
| Q2 FY202510-Q | $25.7B | $14.1B | $3.2B | $11.5B |
| Q1 FY202510-Q | $22.9B | $12.5B | $1.7B | $10.3B |
Cash Flow Highlights
| Period | Operating Income | Net Income | Gross Profit | Shares Outstanding |
|---|---|---|---|---|
| Q3 FY202510-Q | $1.7B | $1.2B | $2.4B | — |
| Q2 FY202510-Q | $1.5B | $1.1B | $2.1B | — |
| Q1 FY202510-Q | $204.5M | $737.8M | $1.6B | — |
Filings
(4)Methodology
Every figure on this page is pulled directly from AMPHENOL CORP /DE/'s own XBRL submissions to the U.S. Securities and Exchange Commission. XBRL is the standardized tagging format the SEC requires for line items in 10-K and 10-Q filings, which means revenue, net income, and balance-sheet entries are reported by the company itself — not estimated by us.
Cayman Journal reconciles preferred GAAP tags (for example, Revenues, RevenueFromContractWithCustomerExcludingAssessedTax) and normalizes them so quarter-over-quarter comparability is preserved. Our automated ingestion runs nightly; markets editors spot-check flagged anomalies before they appear on the public hub. Where a tag is missing for a given period, we surface an em dash rather than impute a value.
Source documents are linked under Filings above and point to the original EDGAR submission index. Errors should be reported to [email protected].